CSL公司旗下的安登布里(Andembry)在安全性方面表现令人满意。一项为期12个月的治疗数据显示,大多数患者在整个治疗周期内始终保持无发作状态。这一结果凸显了该药物的安全性与疗效潜力。
CSL公司旗下的安登布里(Andembry)在安全性方面表现令人满意。一项为期12个月的治疗数据显示,大多数患者在整个治疗周期内始终保持无发作状态。这一结果凸显了该药物的安全性与疗效潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.